×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Acer Therapeutics Inc. (ACER) NASDAQ

$0.90 - (-)

Market Cap: -

As of 11/08/23 12:00 AM EST. Market closed.

(ACER)

Acer Therapeutics Inc. (ACER)
NASDAQ

$0.90
- (-)

Market Cap: -

As of 11/08/23 12:00 AM EST. Market closed.

Add to Portfolio

acer therapeutics is a biotech company, headquartered in cambridge, ma, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. acer's lead candidate, edviso™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type ehlers-danlos syndrome (veds). ehlers-danlos syndrome is a ... read more

acer therapeutics is a biotech company, headquartered in cambridge, ma, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. acer's lead candidate, edviso™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type ehlers-danlos syndrome (veds). ehlers-danlos syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. veds is a subtype characterized by severe arterial dissections, ruptures and early death. complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. median age of death is estimated to be around 50 years. patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the col3a1 gene. there are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the u.s. (pepin 2014). there are no specific pharmacologica read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO Compensation (Base)
$400,000
CEO Compensation (Total)
$550,000
URL
Address
One Gateway Center (300 Washington St.), Suite 351, Massachusetts, Newton, 02458.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Christopher Schelling
CEO Compensation (Base)
$400,000
CEO Compensation (Total)
$550,000
Address
One Gateway Center (300 Washington St.), Suite 351, Massachusetts, Newton, 02458.
PRICE CHART FOR ACER THERAPEUTICS INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$0.87
Previous Close
$0.90
Days Range
$0.85 - $0.92
52 week range
- - -
Volume
424,060
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
24,463,726
Open
$0.87
Previous Close
$0.90
Days Range
$0.85 - $0.92
52 week range
- - -
Volume
424,060
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
24,463,726
FINANCIAL STATEMENTS FOR ACER THERAPEUTICS INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR ACER THERAPEUTICS INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Schelling ChrisPresident & CEONov 29, 2022 Buy$1.22819,6721,000,0002,712,529Dec 01, 2022, 04:02 PM
ASELAGE STEVEDirectorNov 29, 2022 Buy$1.22409,836500,000483,741Dec 01, 2022, 04:01 PM
ASELAGE STEVEDirectorDec 10, 2021 Buy$2.047,98416,28773,905Dec 13, 2021, 04:02 PM
ASELAGE STEVEDirectorDec 09, 2021 Buy$2.152,0164,33465,921Dec 13, 2021, 04:02 PM
ASELAGE STEVEDirectorJul 24, 2020 Buy$3.5045,000157,50063,905Jul 28, 2020, 09:02 AM
DUNN JOHN MICHAELDirectorJul 24, 2020 Buy$3.5021,42874,99827,380Jul 28, 2020, 09:01 AM
Joseph DonaldChief Legal Officer and SecyJul 24, 2020 Buy$3.5014,28549,99814,285Jul 28, 2020, 09:01 AM
Schelling ChrisPresident & CEOJul 24, 2020 Buy$3.50142,857500,0001,892,857Jul 28, 2020, 09:00 AM
Andrews William T.Chief Medical OfficerMar 02, 2020 Option Exercise$3.283,14210,3065,858Mar 04, 2020, 04:25 PM
ASELAGE STEVEDirectorJul 03, 2019 Buy$3.725,00018,58118,905Jul 05, 2019, 04:08 PM
TVM Life Science Ventures VII L.P.DirectorAug 01, 2018 Buy$18.00275,0004,950,0001,697,709Aug 22, 2018, 04:22 PM
TVM Life Science Ventures VI GmbH & Co KGDirectorDec 12, 2017 Buy$12.00333,3333,999,9961,422,709Jan 12, 2018, 02:33 PM
ASELAGE STEVEDirectorDec 14, 2017 Buy$12.002,00024,00013,905Dec 18, 2017, 04:01 PM
BARABE TIMOTHY CDirectorNov 18, 2016 Sale$0.5514,9148,21020,719Nov 22, 2016, 07:31 AM
BARABE TIMOTHY CDirectorSep 17, 2014 Buy$1.1510,00011,50016,000Sep 18, 2014, 08:00 AM
Warma Neil KPresident & CEOSep 16, 2014 Buy$1.1110,00011,100107,634Sep 17, 2014, 08:00 AM
Seaman Scott BDirectorDec 18, 2013 Buy$1.7030,00051,00040,913Dec 18, 2013, 03:58 PM
Radhakrishnan KarthikChief Financial OfficerDec 18, 2013 Buy$1.708,00013,60058,000Dec 18, 2013, 03:55 PM
Warma Neil KPresident & CEOSep 24, 2013 Option Exercise$1.918,07615,42517,315Sep 26, 2013, 09:15 PM
JORDEN DAVID EMERSONDirectorSep 24, 2013 Option Exercise$1.9161,912118,252293,456Sep 26, 2013, 09:00 PM
Seaman Scott BDirectorSep 24, 2013 Option Exercise$1.91269,182514,138518,708Sep 26, 2013, 08:57 PM
Radhakrishnan KarthikChief Financial OfficerAug 08, 2013 Buy$1.5050,00075,00050,000Aug 09, 2013, 08:00 AM
JORDEN DAVID EMERSONDirectorJun 30, 2013 Option Exercise$1.544,4506,853231,544Jul 02, 2013, 02:57 PM
Warma Neil KPresident & CEOJun 30, 2013 Option Exercise$1.545818959,239Jul 02, 2013, 02:49 PM
Seaman Scott BDirectorJun 30, 2013 Option Exercise$1.5419,34529,791249,526Jul 02, 2013, 02:42 PM
Warma Neil KPresident & CEODec 31, 2012 Option Exercise$1.336007988,658Jan 28, 2013, 05:43 PM
Seaman Scott BDirectorDec 31, 2012 Option Exercise$1.3319,97826,571230,181Jan 24, 2013, 06:50 PM
JORDEN DAVID EMERSONActing Chief Financial OfficerDec 31, 2012 Option Exercise$1.334,5956,111227,094Jan 24, 2013, 06:15 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Schelling ChrisPresident & CEO11/29/20221,000,000
ASELAGE STEVEDirector11/29/2022500,000
ASELAGE STEVEDirector12/10/202116,287
ASELAGE STEVEDirector12/09/20214,334
ASELAGE STEVEDirector07/24/2020157,500
DUNN JOHN MICHAELDirector07/24/202074,998
Joseph DonaldChief Legal Officer and Secy07/24/202049,998
Schelling ChrisPresident & CEO07/24/2020500,000
Andrews William T.Chief Medical Officer03/02/202010,306
ASELAGE STEVEDirector07/03/201918,581
TVM Life Science Ventures VII L.P.Director08/01/20184,950,000
TVM Life Science Ventures VI GmbH & Co KGDirector12/12/20173,999,996
ASELAGE STEVEDirector12/14/201724,000
BARABE TIMOTHY CDirector11/18/20168,210
BARABE TIMOTHY CDirector09/17/201411,500
Warma Neil KPresident & CEO09/16/201411,100
Seaman Scott BDirector12/18/201351,000
Radhakrishnan KarthikChief Financial Officer12/18/201313,600
Warma Neil KPresident & CEO09/24/201315,425
JORDEN DAVID EMERSONDirector09/24/2013118,252
Seaman Scott BDirector09/24/2013514,138
Radhakrishnan KarthikChief Financial Officer08/08/201375,000
JORDEN DAVID EMERSONDirector06/30/20136,853
Warma Neil KPresident & CEO06/30/2013895
Seaman Scott BDirector06/30/201329,791
Warma Neil KPresident & CEO12/31/2012798
Seaman Scott BDirector12/31/201226,571
JORDEN DAVID EMERSONActing Chief Financial Officer12/31/20126,111
Load More Insider Transactions
FUNDS WITH A POSITION IN ACER THERAPEUTICS INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
TUDOR INVESTMENT CORP ET AL927,0410.00758%ExitedEvent Driven, Other
GEODE CAPITAL MANAGEMENT, LLC136,9550.00001%ExitedOther
BLACKROCK INC.76,7720%ExitedOther
UNION SQUARE PARK CAPITAL MANAGEMENT, LLC26,6330.02%ExitedEvent Driven
CHANGE IN SHARES OUTSTANDING FOR ACER THERAPEUTICS INC
STOCK BUYBACKS FOR ACER THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
06/30/2023
03/31/2023
15.87%
1Q
06/30/2023
06/30/2022
38.35%
4Q

Period of Report: 06/30/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
03/31/2023
15.87%
1Q
06/30/2022
38.35%
4Q
BUYBACK ANNOUNCEMENT(S) FOR ACER THERAPEUTICS INC
LOADING...